Fractalkine is a new member of chemokine family, which exists in membrane-boundd form and soluble form. It has both adhesion molecular and chemokine activities. CX3 CR1 is its specific receptor. Both of them were expressed in many diseases of the nervous system. At present, fractalkine and its receptor CX3CR1 polymorphism and the research of cerebrovascular diseases mainly involve in the risk factors for cerebrovascular diseases, cerebral ischemia-reperfusion and bone marrow stem cell transplantion, which are expected to become a new target for clinical treatment.

Objective To explore the relationships between personality traits and internet addiction disorder, as well as which traits would affect internet addiction, and to provide the psychology basis against internet disorder in teenage. Methods The Cattell 16 Personality Factor Questionnaire (16PF) and Chinese Internet Disorder Scale were applied to 409 undergraduates and high school students in Changsha. Use SPSS for windows 11.0 to carry on statistical processing. Results (1) Rule consciousness personality trait certain forecast internet disorder total score ( t = 3.18 ), withdrawal factor ( t = 4.17 ), tolerant factor ( t = 2.64) and time manage factor ( t =3.01 ). (2) Abstractedness personality trait certain forecast internet disorder total score ( t = 2.47 ) and interpersonal and healthy factor ( t = 3.08 ). (3) Warmth personality trait certain forecast forced-internet behavior factor ( t = 2.14 ) and time manage factor ( t = 2.41 ). (4) Social Boldness personality trait certain forecast interpersonal and healthy factor ( t = 2.42). Conclusion Personality traits certain influence internet addiction disorder.

BACKGROUND:Bone morphogenetic protein 9 is proved to promote the osteogenic differentiation of various kinds of stem cel s, but whether it can induce the osteogenic differentiation of dental fol icle cel s in vitro is yet unclear. OBJECTIVE:To investigate whether bone morphogenetic protein 9 can induce the osteogenic differentiation of rat dental fol icle cel s in vitro. METHODS:Purified rat dental fol icle cel s at passage 3 were transfected with bone morphogenetic protein 9 adenovirus. Then, alkaline phosphatase activity, calcium deposition and expression of osteogenesis-related factors at mRNA and protein levels were detected in the dental fol icle cel s. RESULTS AND CONCLUSION:After transfection with bone morphogenetic protein 9, the dental fol icle cel s showed continuously enhanced alkaline phosphatase activities and obviously enhanced calcium deposition. Real-time PCR results demonstrated that the mRNA expressions of alkaline phosphatase, osteocalcin, bone sialoprotein, osteopontin and core binding factor were increased significantly. The western blot assay showed that the expression of osteopontin enhanced in the dental fol icle cel s after transfection with bone morphogenetic protein 9. In summary, bone morphogenetic protein 9 can induce the osteogenic differentiation of dental fol icle cel s.

Objective:To investigate the efficacy of montelukast in the treatment of children with asthma and its influence on the serum levels of metalloprotease-9 (MMP-9) and metal protease inhibitor-1 (TIMP-1).Methods:Totally 90 cases of asthma children were selected and divided into the control group and the observation group with 45 ones in each .The control group was treated with the conventional symptomatic treatment , and the observation group was treated with montelukast chewable tablets additionally , and the treatment course was 8w.The effectiveness adverse reactions were compared between the groups , and the lung function indices and the changes of MMP-9 and TIMP-1 levels of the two groups were compared as well .Results: The total effective rate of the observation group (93.33%) was significantly better than that of the control group (P<0.05).After the treatment, the levels of FEV1 and PEF were significantly higher than those before the treatment in the two groups , the levels of MMP-9 and TIMP-1 were notably lower than those before the treatment in both groups , and the changes in the observation group were more significant than those in the control group (P<0.05).There were no adverse drug reactions in both groups .Conclusion:Montelukast combined with the conventional therapy can down-regulate the serum levels of MMP-9 and TIMP-1 and inhibit airway remodeling resulting in improved curative effect with high safety.

In clinical teaching we should not only train the students in scientific clinical thinking manner and inform them of recent progress of cardiovascular system,but also cultivate their information quality,improve their ability of applying medical English and enhance their consciousness of medical disputes prevention.

Objective An experimental study was undertaken to observe the effects of DFMO on the growth and apoptosis in bladder carcinoma EJ cells. Methods The methods of cell culture, living camera technique, eosin dying cell counting and DNA end labeling in situ were used to observe the effects of DFMO on the growth and apoptosis in bladder carcinoma EJ cells. Results Living camera technique showed that cell growth was significantly inhibited after five days of 4 mmol/L, 6 mmol/L, 8 mmol/L of DFMO were administrated compared with that of control group, and this variation was obvious with DFMO dosage increasing. The same was observed with eosin dying cell counting. Tunel method showed that apoptosis was induced by DFMO with 4 mmol/L, 6 mmol/L, and 8 mmol/L, but 6 mmol/L seems to be a suitable dosage. All these methods showed that if exogenous putrescence was added simultaneously, there was no difference significantly compared with that of control group both in cell proliferation and apoptosis. Conclusion The proliferation of bladder carcinoma EJ cell could be inhibited by DFMO and also apoptosis could be induced by DFMO.

Objective To Study the clinical characteristics of the :sick sinus syndrome,(SSS) in elderly patients.Methods The disease onset age and causes, natural course and symptoms,dynamic electrocardiography(DCG) and cardiac pacing occasion were reviewed and analyzed. in 50 elderly patients had the diagnosis of SSS.Results The morbidity of SSS had increased significantly in elderly men over 70 years. The ordinary causes were coronary heart disease (CHD),specific SSS and the hypertensive heart disease,cardiomyopathy; and degenerative valvular heart disease etc.The mean natural course were about 10 years.The course of DCG type III was the longest one and the type IV was the shortest. The early symptoms were palpitation, dizzy and weakness,and the late symptoms were transient amaurosis, syncope and the worse cardiac angina and heart failure .The cardiac pacing was predicated by the clinical symptom's severity, which was determinated by both of the severity of bradycardia or sinus arrest and the patient's ability of compensation and adaptation.DCG was the commonly used diagnostic method for SSS in elderly patients.Conclusions The SSS has high incidence in elderly men over 70 and is caused by kinds of deasese,such as CHD and specific SSS,etc.The course is frequently intermittent,hide and very long the disease course. The early symptoms and DCG are atypical. The late symptoms commonly are transient amaurosis and syncope .and the late DCG has four types.The cardiac pacing was predicated by the clinical symptom's severity and DCG was the commonly used to diagnose SSS in elderly patients.

Systemic lupus erythematosus(SLE) is an autoimmune disease characterized by the production of autoantibodies against a wide spectrum of nuclear, cytoplasmic,and cell membrane autoantigens.Among them,the anti-Smith antibodies are specific for SLE and thus have been included as a criteria for diagnosis.They are not only a diagnostic marker but also a reliable measure of disease activity in SLE,we intend to describe the biological functions and clinical significance of the Smith antigen and the detection of anti-Smith antibodies.

Anti-Arrhythmia Agents ; therapeutic use ; Arrhythmias, Cardiac ; drug therapy ; Child ; Humans ; Sotalol ; therapeutic use

Acute Disease ; Humans ; Pulmonary Embolism ; therapy